Pfizer Inc & BioNTech SE agreed to supply 120 mil doses of experimental COVID vaccine to Japan

Pfizer Inc and BioNTech SE said on Friday that in the first half of 2021 they have a agreement to supply 120 million doses of their experimental coronavirus vaccine to Japan.

Financial details of the agreement are confidential and company did not disclosed as of now, but said terms were based on the volume of doses and the timing of the delivery.

Read Also – IBM partners with Japanese business to speed up advances in quantum computing

The United States has also signed a similar deal with Pfizer and BioNtech for 100 million doses for nearly $2 billion, which amounts to a $39 price tag for what is likely to be a two dose treatment course.

As there is no current vaccine for COVID-19 and also due to the disease, it has claimed 670,000 lives and slow down of economies, Moreover there are over 150 vaccines in various stages of development against the still fast-spreading virus.

Pfizer Inc & BioNTech SE on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy.

Another relaxing news are from Daiichi Sankyo Co is in discussions to provide supplies of a potential coronavirus vaccine being developed by AstraZeneca Plc and the University of Oxford for use in Japan.

As early as October assuming clinical success of the vaccines, Pfizer and BioNtech said they are on track to seek regulatory review for the vaccine.

Leave a Reply